Zenlabs Ethica Limited share price
BSE: ZENLABS
Key numbers
- Market cap
- ₹ 18.2 Cr
- Current price
- ₹ 28.02
- 52-week high / low
- ₹ 40 / 17
- Stock P/E
- -
- Book value
- ₹ 13.0
- Dividend yield
- 0.00%
- ROCE
- -4.8%
- ROE
- -20.5%
- Debt to equity
- 1.29
- Sales growth (3 yrs)
- -11.1%
- Profit growth (3 yrs)
- -
- 1-year return
- -13.5%
About Zenlabs Ethica Limited
Zenlabs Ethica Limited markets and distributes pharmaceutical products primarily in India. It markets analgesics and anti-inflammatory drugs; skin preparations; drugs for neurological and GIT disorders; ear, eye, and nasal drops; anti-diabetic, anti-depressant, anti-infective, anti-emetic, anti-hypertensive, anti-allergic, and anti-cold and cough syrups; steroids and anabolic steroids; nutraceuticals; antacids, enzymes, and appetite stimulants; ayurvedic preparations; soaps; dusting powders; soaps; and other pharmaceutical drugs. The company is also involved in the private label manufacturing of various pharmaceutical products, such as tablets, capsules, injections, syrups, and ointments; and therapeutics, such as anti-infective, anti-obesity, anti-bacterial, anti-hypertensives, anti-fungal, pain killers, and nutritional supplements. It serves customers through a network of distributors and stockists in Myanmar, Indonesia, Malaysia, Thailand, Cambodia, Vietnam, Laos, the Philippines, Singapore, Brunei, Timor-Leste, Bangladesh, and internationally. The company was formerly known as Neelkanth Technologies Limited and changed its name to Zenlabs Ethica Limited in January 2016.…
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 11 | 12 | 12 | 11 | 14 |
| Operating profit | 1 | 0 | 1 | 0 | -0 |
| Net profit | 0 | 0 | -2 | 0 | -1 |
| EPS (₹) | 0.05 | 0.06 | -3.08 | 0.00 | -0.88 |
Peers in Medical Distribution
Data for information only, not investment advice. Prices end of day.